JP2024543347A - 筋萎縮性側索硬化症を治療する方法およびそれに対する投与計画 - Google Patents

筋萎縮性側索硬化症を治療する方法およびそれに対する投与計画 Download PDF

Info

Publication number
JP2024543347A
JP2024543347A JP2024526916A JP2024526916A JP2024543347A JP 2024543347 A JP2024543347 A JP 2024543347A JP 2024526916 A JP2024526916 A JP 2024526916A JP 2024526916 A JP2024526916 A JP 2024526916A JP 2024543347 A JP2024543347 A JP 2024543347A
Authority
JP
Japan
Prior art keywords
treatment
patient
fasudil
als
phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543347A5 (https=
Inventor
マカリスター，トーマス
ジェイコブソン，スヴェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Woolsey Pharmaceuticals Inc
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of JP2024543347A publication Critical patent/JP2024543347A/ja
Publication of JP2024543347A5 publication Critical patent/JP2024543347A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024526916A 2021-11-12 2022-11-10 筋萎縮性側索硬化症を治療する方法およびそれに対する投与計画 Pending JP2024543347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278523P 2021-11-12 2021-11-12
US63/278,523 2021-11-12
PCT/US2022/049541 WO2023086468A1 (en) 2021-11-12 2022-11-10 Method of treating amyotrophic lateral sclerosis and dosing regimen for same

Publications (2)

Publication Number Publication Date
JP2024543347A true JP2024543347A (ja) 2024-11-21
JP2024543347A5 JP2024543347A5 (https=) 2025-11-12

Family

ID=86336738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526916A Pending JP2024543347A (ja) 2021-11-12 2022-11-10 筋萎縮性側索硬化症を治療する方法およびそれに対する投与計画

Country Status (7)

Country Link
US (1) US20240415846A1 (https=)
EP (1) EP4429667A4 (https=)
JP (1) JP2024543347A (https=)
CN (1) CN118251226A (https=)
CA (1) CA3236338A1 (https=)
MX (1) MX2024005745A (https=)
WO (1) WO2023086468A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025207476A1 (en) * 2024-03-25 2025-10-02 Woolsey Pharmaceuticals, Inc. Methods for treating als with a rho kinase inhibitor based on use of neurofilament light chain biomarker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050783A2 (en) * 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US9980972B2 (en) * 2012-03-12 2018-05-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating familial amyotrophic lateral sclerosis
US20180055887A1 (en) * 2016-08-23 2018-03-01 Academia Sinica Method for preparing induced mesenchymal stem cells and improving mesenchymal stem cell's characters and its applications
US11642352B2 (en) * 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia

Also Published As

Publication number Publication date
CN118251226A (zh) 2024-06-25
EP4429667A1 (en) 2024-09-18
CA3236338A1 (en) 2023-05-19
US20240415846A1 (en) 2024-12-19
MX2024005745A (es) 2024-05-28
WO2023086468A1 (en) 2023-05-19
EP4429667A4 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
US20260098052A1 (en) Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same
Crook et al. The binding of [3H] AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia
US20250228868A1 (en) Method of treating amyotrophic lateral sclerosis
IL302839A (en) Novel rna transcript
JP2024543347A (ja) 筋萎縮性側索硬化症を治療する方法およびそれに対する投与計画
EP4551228A1 (en) Regimen for treating amyotrophic lateral sclerosis having onset 24 months prior to treatment
EP4103187B1 (en) Fasudil for treating pseudobulbar affect
EP3510029B1 (en) Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
JP2024537981A (ja) 筋萎縮性側索硬化症を治療する方法
EP4551227A1 (en) Treating amyotrophic lateral sclerosis having onset 24 months prior to treatment
WO2024081763A1 (en) Method of treating amyotrophic lateral sclerosis by oral administration of fasudil
WO2025160116A1 (en) Methods of treating amyotrophic lateral sclerosis by oral administration of fasudil
US20240009180A1 (en) Medicine for alleviating neuropathic pain
WO2025207476A1 (en) Methods for treating als with a rho kinase inhibitor based on use of neurofilament light chain biomarker
AU2020324937B2 (en) Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same
HK40094114A (en) Medicine for alleviating neuropathic pain
US20230310447A1 (en) Methods of treating age-related cognitive decline
EP3718549A1 (en) Novel pharmaceutical composition for treatment of dystonia
Robberecht et al. Amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251021